Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus

Curr Opin Pharmacol. 2004 Dec;4(6):589-96. doi: 10.1016/j.coph.2004.08.005.

Abstract

Proof-of-concept for the efficacy of a glucagon-like peptide 1 (GLP-1)-based therapy of patients with type 2 diabetes was provided in 2002 by means of prolonged continuous subcutaneous infusion of native GLP-1. Since then, several long-acting analogues of GLP-1, as well as inhibitors of dipeptidyl peptidase IV, the enzyme that rapidly inactivates endogenous GLP-1, have demonstrated efficacy in long term clinical trials.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dipeptidyl Peptidase 4 / drug effects*
  • Dipeptidyl Peptidase 4 / metabolism
  • Glucagon / pharmacology
  • Glucagon / therapeutic use*
  • Glucagon-Like Peptide 1
  • Humans
  • Peptide Fragments / pharmacology
  • Peptide Fragments / therapeutic use*
  • Protease Inhibitors / pharmacology
  • Protease Inhibitors / therapeutic use*
  • Protein Precursors / pharmacology
  • Protein Precursors / therapeutic use*
  • United Kingdom

Substances

  • Peptide Fragments
  • Protease Inhibitors
  • Protein Precursors
  • Glucagon-Like Peptide 1
  • Glucagon
  • Dipeptidyl Peptidase 4